{
    "nct_id": "NCT01352598",
    "official_title": "Phase IV Trial Evaluating the Use of Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer",
    "criteria": {
        "raw_text": "Inclusion Criteria:\n\n* Patient age \\>= 18 years\n* Zubrod performance status of 0-3\n* T1-3 N0 M0 adenocarcinoma of the prostate\n* Prostate volume ≤ 100 cc\n* Signed study-specific consent form\n\nExclusion Criteria\n\n* Extension of local tumor to involve adjacent organs other than seminal vesicles (T4)\n* Prostate volume \\> 100 cc\n* Nodal involvement\n* Metastatic disease\n* Prior pelvic radiotherapy except as part of combination therapy for prostate cancer\n* History of scleroderma\n* Patients with psychiatric or addictive disorder that would preclude obtaining informed consent\n\nsex: MALE\n\nminimumAge: 18 Years\n\nstdAges: ['ADULT', 'OLDER_ADULT']",
        "inclusion": "* Patient age >= 18 years\n* Zubrod performance status of 0-3\n* T1-3 N0 M0 adenocarcinoma of the prostate\n* Prostate volume ≤ 100 cc\n* Signed study-specific consent form",
        "exclusion": "* Extension of local tumor to involve adjacent organs other than seminal vesicles (T4)\n* Prostate volume > 100 cc\n* Nodal involvement\n* Metastatic disease\n* Prior pelvic radiotherapy except as part of combination therapy for prostate cancer\n* History of scleroderma\n* Patients with psychiatric or addictive disorder that would preclude obtaining informed consent"
    }
}